Trial Profile
A phase II trial of lapatinib and capecitabine for patients with refractory advanced colorectal adenocarcinoma (LAP109859)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Lapatinib (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 21 May 2010 Actual patient number (29) added as reported by ClinicalTrials.gov.
- 21 May 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 21 May 2010 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.